Smart Blog

IoT Medical: Celgene joins IBM Watson Health Forge

Celgene joins IBM Watson Health Forge

by Tim Cole

Celgene Corporation, a biopharmaceutical company headquartered in Summit, New Jersey, is engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases. They are joining forces with IBM to co-develop Watson for Patient Safety, running in the Watson Health Cloud.

Collaboration: IBM Celgene-

Left to right: Celgene Head of Global Safety Operations, Ed Mingle; IBM Watson Health’s Vice President of Life Sciences, Lauren O’Donnell and General Manager, Deborah DiSanzo at the Fortune Brainstorm Health 2016 conference in San Diego.

This new offering aims to enhance pharmacovigilance methods used to collect, assess, monitor, and report adverse drug reactions. As Watson’s cognitive computing engine continuously learns, it is expected that Watson for Patient Safety will increasingly be able to help identify potential drug safety signals.
The offering is designed to enable the rapid collection, collation and automated analysis of high volumes of data from electronic medical records, medical claims databases and other healthcare information sources. Across the biopharmaceutical industry these reports are increasing in volume and complexity as data sources grow and regulations evolve.
Celgene and IBM are hoping to help biopharmaceutical companies to better manage and interpret large volumes of Individual Case Safety Reports (ICSRs) describing potential side effects associated with drug products.

Image credit: IBM


Leave a Reply

Your email address will not be published. Required fields are marked *